Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential

Trends in Endocrinology and Metabolism

Volumn 10, Issue 6, 1999, Pages 229-235

  Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; GLICENTIN; GLUCAGON; GLUCOSE;

ANIMAL MODEL; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INTESTINE MOTILITY; INTESTINE MUCOSA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; APPETITE; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GLUCAGON RELEASE; GLUCONEOGENESIS; HORMONE RELEASE; HUMAN CELL; HYPOGLYCEMIA; INSULIN SYNTHESIS; NUTRITION; PANCREAS CELL;

EID: 0033175006     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00157-5     Document Type: Review

References (74)

1. Bell G.I., Sanchez-Pescador R., Laybourn P.J., Najarian R.C. Exon duplication and divergence in the human preproglucagon gene. Nature. 304:1983;368-371.
2. Mojsov S.et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261:1986;11880-11889.
3. Bell G.I., Santerre R.F., Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 302:1983;716-718.
4. Orskov C.et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 119:1986;1467-1475.
5. Holst J.J.et al. Proglucagon processing in porcine and human pancreas. J. Biol. Chem. 269:1994;18827-18833.
6. Holst J.J. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin - current status. Gastroenterology. 84:1983;1602-1613.
7. Bataille D., Jarrousse C., Kervran A., Depigny C., Dubrasquet M. The biological significance of 'enteroglucagon'. Present status. Peptides. 7(Suppl. 1):1986;37-42.
8. Baldissera F.G., Holst J.J., Knuhtsen S., Hilsted L., Nielsen O.V. Oxyntomodulin [glicentin-(33-69)]: pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 21:1988;151-166.
9. Holst J.J. Enteroglucagon. Annu. Rev. Physiol. 59:1997;257-271.
10. Elliott R.M.et al. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 138:1993;159-166.
11. Orskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:1996;665-670.
12. Layer P., Holst J.J., Grandt D., Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 40:1995;1074-1082.
13. Miholic J., Orskov C., Holst J.J., Kotzerke J., Meyer H.J. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci. 36:1991;1361-1370.
14. Schirra J.et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest. 97:1996;92-103.
15. Holst J.J., Orskov C., Nielsen O.V., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:1987;169-174.
16. Fehmann H.C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16:1995;390-410.
17. Gromada J., Holst J.J., Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch. 435:1998;583-594.
18. Egan J.M., Zhou J., Perfetti R., Elahi D. GLP-1 is a trophic factor. Dig. Dis. Sci. 43:1998;1902. (abstr.).
19. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. ii:1987;1300-1304.
20. Kolligs F., Fehmann H.C., Goke R., Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 44:1995;16-19.
21. Wang Z.et al. Glucagon-like peptide-1 is a physiological incretin in rat [see comments]. J. Clin. Invest. 95:1995;417-421.
22. Edwards C.M.et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 48:1999;86-93.
23. Scrocchi L.A.et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:1996;1254-1258.
24. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:1993;912-917.
25. Orskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 123:1988;2009-2013.
26. Hvidberg A., Nielsen M.T., Hilsted J., Orskov C., Holst J.J. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism. 43:1994;104-108.
27. Valverde I., Villanueva-Penacarrillo M.L. In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol. Scand. 1996 158, 297]. Acta Physiol. Scand. 157:1996;359-360.
28. Furnsinn C., Ebner K., Waldhausl W. Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia. 38:1995;864-867.
29. Hansen B.F., Jensen P., Nepper-Christensen E., Skjolstrup B. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol. 35:1998;101-103.
30. Toft-Nielson M., Madsbad S., Holst J.J. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes. 45:1996;552-556.
31. Orskov L.et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia. 39:1996;1227-1232.
32. Wettergren A.et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:1993;665-673.
33. Nauck M.A.et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273:1997;E981-E988.
34. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101:1998;515-520.
35. Gutzwiller J.P.et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 44:1999;81-86.
36. Orskov C., Poulsen S.S., Moller M., Holst J.J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 45:1996;832-835.
37. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7:1995;2294-2300.
38. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403:1999;261-280.
39. Larsen P.J., Tang-Christensen M., Holst J.J., Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 77:1997;257-270.
40. Turton M.D.et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature. 379:1996;69-72.
41. Tang-Christensen M.et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271:1996;R848-R856.
42. Toft-Nielsen M-B., Madsbad S., Holst J.J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycemia. Diabetologia. 41:1998;1180-1186.
43. Holst J.J., Schwartz T.W., Lovgreen N.A., Pedersen O., Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int. J. Obes. 7:1983;529-538.
44. Naslund E.et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int. J. Obes. Relat. Metab. Disord. 21:1997;387-392.
45. Ranganath L.R.et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 38:1996;916-919.
46. Naslund E.et al. Energy intake and appetite is suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. 23:1999;304-311.
47. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:1991;415-423.
48. O'Harte F.P., Abdel-Wahab Y.H., Conlon J.M., Flatt P.R. Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia. 41:1998;1187-1193.
49. Mooney M., Kelly C.M.N., Flatt P.R., O'Harte F.P.M. Aminopeptidase resistant glycated glucagon-like peptide-1 (7-36)amide shows potent insulinotropic action in vivo. Diabetologia. 41:1998;A183. (abstr.).
50. Tanizawa Y.et al. Human glucagon-like peptide-1 receptor gene in NIDDM. Identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes. 43:1994;752-757.
51. Zhang Y.et al. Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young. Diabetologia. 37:1994;721-724.
52. Vaag A.A., Holst J.J., Volund A., Beck-Nielsen H.B. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur. J. Endocrinol. 135:1996;425-432.
53. Holst J.J., Gromada J., Nauck M.A. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia. 40:1997;984-986.
54. Gutniak M., Orskov C., Holst J.J., Ahren B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus [see comments]. New Engl. J. Med. 326:1992;1316-1322.
55. Nauck M.A.et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:1993;301-307.
56. Nauck M.A.et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
57. Creutzfeldt W.O.et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 19:1996;580-586.
58. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 40:1997;205-211.
59. Larsen J., Jallad J., Damsbo P. One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes. 45:1996;233A. (abstr.).
60. Larsen J., Damsbo P. GLP-1 must be present continuously in order to obtain a good glycaemic control in NIDDM. Diabetes. 46:1997;186A. (abstr.).
61. Nauck M.A.et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 39:1996;1546-1553.
62. Todd J.F.et al. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 27:1997;533-536.
63. Ritzel R., Orskov C., Holst J.J., Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. 38:1995;720-725.
64. Knudsen L.B., Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318:1996;429-435.
65. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
66. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
67. Holst J.J. Treatment of type 2 diabetes with glucagonlike peptide 1. Curr. Opin. Endocrinol. Diabetes. 5:1998;108-115.
68. Toft-Nielsen M-B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of GLP-1 lowers blood glucose and reduces appetite in NIDDM patients. Diabetologia. 41:1998;A61. (abstr.).
69. Deacon C.F.et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 41:1998;271-278.
70. Ritzel U., Fromme A., Ottleben M., Leonhardt U., Ramadori G. Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetol. 34:1997;18-21.
71. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type II diabetes mellitus. Diabetes. 47:1998;1663-1670.
72. Deacon C.F., Hughes T.E., Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulino-tropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 47:1998;764-769.
73. Pederson R.A.et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
74. Turner R.C. The U.K. prospective diabetes study. A review. Diabetes Care. 21(Suppl. 3):1998;C35-C38.